Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
复制标题

高三尖杉酯碱与阿克拉霉素和阿糖胞苷联合协同诱导 t(8;21) 白血病细胞凋亡,并触发 caspase-3 介导的 AML1-ETO 癌蛋白裂解

DOI:
10.1002/cam4.913
复制
发表时间:
2016-11
期刊:
影响因子:
4
通讯作者:
Xu, Kai-Lin
Xu, Kai-Lin
中科院分区:
医学3区
文献类型:
--
作者:
Cao, Jiang;Feng, Hao;Ding, Ning-Ning;Wu, Qing-yun;Chen, Chong;Niu, Ming-Shan;Chen, Wei;Qiu, Ting-Ting;Zhu, Hong-Hu;Xu, Kai-Lin

文献摘要

参考文献

被引文献

相似文献

高三尖杉酯碱联合阿克拉霉素和阿糖胞苷(HAA)是治疗急性髓系白血病(AML)的高效药物,尤其是t(8;21) AML。然而,HAA 杀死 t(8;21) AML 细胞的潜在机制仍不清楚。在本研究中,使用了带有 t(8;21) 的 SKNO-1 和 Kasumi-1 细胞。与单独或成对施用高三尖杉酯碱、阿柔比星或阿糖胞苷相比,HAA 对 SKNO-1 和 Kasumi-1 细胞的生长和诱导凋亡表现出最强的抑制作用。 HAA 导致 AML1-ETO (AE) 癌蛋白裂解形成截短的 AE (ΔAE)。使用 caspase-3 抑制剂 caspase-3 抑制剂 Q-DEVD-OPh (QDO) 进行预处理不仅抑制了 HAA 诱导的细胞凋亡,还消除了 AE 的裂解和 ΔAE 的产生。这些结果表明,HAA 协同诱导 t(8;21) 白血病细胞凋亡,并触发 caspase-3 介导的 AML1-ETO 癌蛋白裂解,从而为 HAA 对 t(8;21) AML 的强活性提供了直接证据。
Homoharringtonine combined with aclarubicin and cytarabine (HAA) is a highly effective treatment for acute myeloid leukemia (AML), especially for t(8;21) AML. However, the underlying mechanisms by which HAA kills t(8;21) AML cells remain unclear. In this study, SKNO‐1 and Kasumi‐1 cells with t(8;21) were used. Compared with individual or pairwise administration of homoharringtonine, aclarubicin, or cytarabine, HAA showed the strongest inhibition of growth and induction of apoptosis in SKNO‐1 and Kasumi‐1 cells. HAA caused cleavage of the AML1‐ETO (AE) oncoprotein to form truncated AE (ΔAE). Pretreatment with the caspase‐3 inhibitor caspase‐3 inhibitor Q‐DEVD‐OPh (QDO) not only suppressed HAA‐induced apoptosis but also abrogated the cleavage of AE and generation of ΔAE. These results suggest that HAA synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein, thus providing direct evidence for the strong activity of HAA toward t(8;21) AML.
DOI: 10.1186/1756-8722-2-32
发表时间: 2009-07-30
影响因子: 28.5
作者:
Wang J;Lü S;Yang J;Song X;Chen L;Huang C;Hou J;Zhang W
通讯作者: Zhang W
DOI: 10.1182/blood-2012-10-462879
发表时间: 2013-03-21
期刊: BLOOD
影响因子: 20.3
作者:
Jourdan, Eric;Boissel, Nicolas;Dombret, Herve
通讯作者: Dombret, Herve
DOI: 10.1182/blood-2006-06-032250
发表时间: 2007-04-15
期刊: BLOOD
影响因子: 20.3
作者:
Zhou, Guang-Biao;Kang, Hui;Chen, Zhu
通讯作者: Chen, Zhu
MRD 导向的风险分层治疗可能会改善 t(8;21) AML 在首次完全缓解时的结局:AML05 多中心试验的结果
DOI: 10.1182/blood-2012-11-468348
发表时间: 2013-05-16
期刊: BLOOD
影响因子: 20.3
作者:
Zhu, Hong-Hu;Zhang, Xiao-Hui;Huang, Xiao-Jun
通讯作者: Huang, Xiao-Jun
DOI: 10.1038/sj.leu.2404287
发表时间: 2006-08-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Jin, J.;Jiang, D-Z;Xu, W-L
通讯作者: Xu, W-L